Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,

Slides:



Advertisements
Similar presentations
Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Advertisements

POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
DNA methylation as an epigenetic marker in HIV-2 disease in West Africa? Alberta Davis MRC Laboratories, Gambia 18th January 2013.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Baseline Antiretroviral Resistance Testing among HIV-Positive Injection Drug Users in a Canadian Setting Nadia Fairbairn 1 M-J Milloy 1 Thomas Kerr 1,
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.
Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Lessons Learned from Transient Remission Cases: Clues to Biomarkers of HIV Rebound Katherine Luzuriaga, MD University of Massachusetts.
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Phar. Nhat Mang/ Roche Vietnam
Immune reconstitution Anjie Zhen, PhD
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
Long-term clinical and viro-immunologic outcomes of post-treatment controllers (PTCs) in the ANRS-VISCONTI study Laurent HOCQUELOUX, MD Orléans’ Regional.
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
Emory University School of Medicine Department of Medicine
HIV Cure: Current Status and Future Perspectives
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.
Feedback meeting September 2017
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.
The role of CD4 in patient monitoring Amsterdam July 2018
The block-and-lock approach
Follicular CD8+ T-cells (fCD8) in GALT are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during PHI John Thornhill Imperial.
Cepheid Symposium, IAS 23rd July 2018
HIV-1 specific restriction factors increase in response to viral rebound after analytical treatment interruption De Scheerder Marie-Angélique, Van Hecke.
Volume 5, Issue 1, Pages e35-e44 (January 2018)
Presentation transcript:

Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere, Pawel Bonczkowski, Maja Kiselinova, Karen Vervisch, Wim Trypsteen, Margaret Johnson, Chris Verhofstede, Danny de Looze, Charles Murray, Sabine Kinloch-de Loes, Linos Vandekerckhove HIV Translational Research Unit (HTRU) Ghent University, Ghent, Belgium 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada, July 2015

Background: HIV-1 reservoir Persistent long-lived reservoir: one of the major obstacles to achieve an HIV-1 cure Reservoir: integrated HIV-1 DNA that is replication competent copies ART HIV-1 reservoir Time Viral load ART stop = Viral rebound

Early initiation of ART: is associated with reduced HIV-1 reservoir may lead to post-treatment viral control (VISCONTI controllers 1 ) START study: early ART: lower risk of developing AIDS or other serious ilnesses In a treatment interruption study (SPARTAC 2 ), total HIV-1 DNA correlates with time to viral rebound Better understanding of HIV-1 reservoir can guide therapeutic strategies towards a functional cure 1 Saez-Cirion et al., Plos Pathog Williams et al., eLife Background: Early ART

To assess the long-term impact of early ART on HIV-1 reservoir in blood and gut mucosa To compare the reservoirs between: early or late treated patients LTNPs, representing virological control without ART acute seroconverters as early stage viremic patients Can a decade of ART initiated during primary HIV-1 infection reduce the HIV-1 reservoir to the levels found in LTNPs? Aim of the study

PHI: Primary HIV-1 infection A cross-sectional, observational study Patients consisted of 4 defined cohorts in 2 clinical centers: PHI ART * Early ART PHI Late ART ART PHI LTNP no ART PHI no ART (n=25) (n=17) (n=32) (n=10) ART no ART Patient cohorts years (total=84) 10 years * Fiebig: II-IV (n=10), V (n=15)

Value for cohort* PHILate ARTEarly ARTLTNP n=10N=32n=25n=17 Clinical characteristics Age (years)39 (30-46)48 (31-53)44 (34-53)49 (31-51) Number of females (%)1 (10)5 (15.6)0 (0)7 (41.2) Total ART duration (years)09.8 ( )10.8 ( )0 Viremia zenith (log 10 HIV-1 c/ml)6.2 ( )4.9 ( )5.5 ( )2.5 ( ) CD4 count, nadir (cells/mm 3 )440 ( )155 (0-266)390 ( )624 ( ) CD4 count at sampling (cells/ mm 3 )440 ( )624.5 ( )714 ( )793 ( ) CD4/CD8 ratio0.62 ( )0.74 ( )1.10 ( )0.91 ( ) * Values are reported as median (IQR) Study participant characteristics

HIV-1 reservoir size integrated HIV-1 DNA total HIV-1 DNA Ongoing replication (2-LTR circles) Transcriptional activity (HIV-1 usRNA) HIV-1 reservoir size and dynamics

Materials and methods HIV-1 reservoir size and dynamics: newly-developed PCR- based quantification methods: Total HIV-1 DNA, 2-LTR 1 and usRNA 2 measured by ddPCR Integrated HIV-1 DNA by repetitive sampling Alu-HIV PCR 3 Differences between cohorts: Wilcoxon signed-rank test Correlations: Linear regression 1 Malatinkova et al., J Clin Microbiol Kiselinova et al., PLoS One De Spiegelaere et al., Clin Chem. 2014

Results: HIV-1 DNA reservoir size in blood

Reduced total HIV-1 DNA in early vs late, however not reaching LTNP levels Early ART (n=25) PHI (n=10) LTNP (n=17) Late ART (n=32) p=0.015* p<0.001* p=0.041* p<0.001*

Results: HIV-1 DNA reservoir size in blood

Reduced integrated HIV-1 DNA in early vs late, however not reaching LTNP levels Early ART (n=25) PHI (n=10) LTNP (n=17) Late ART (n=32) p=0.021* p<0.001* p=0.003* p=0.006*p=0.002*p=0.104

Results: HIV-1 reservoir dynamics in blood

Early ART (n=25) PHI (n=10) LTNP (n=17) Late ART (n=32) Episomal 2-LTR circles high in recent ART-naïve seroconverters p=0.595 p=0.743 p=0.259 p=0.002* p<0.001*

Results: HIV-1 reservoir dynamics in blood

Cell-associated HIV-1 usRNA lower in early vs late treated patients and not different from LTNP levels Early ART (n=24) PHI (n=10) LTNP (n=17) Late ART (n=30) p=0.615 p=0.027* p=0.007* p=0.117p=0.092p=0.426

Results: CD4/CD8 ratio

Higher CD4/CD8 ratio in LTNPs and early vs late treated patients Early ART (n=25) LTNP (n=17) PHI (n=10) Late ART (n=32) p=0.978 p=0.036* p=0.009* p=0.007*p=0.048*p=0.448

Negative correlation: CD4/CD8 ratio and integrated HIV-1 DNA in blood R 2 =0.14, p<0.01

Results: HIV-1 DNA reservoir size in rectal biopsies

Total HIV-1 DNA in rectal biopsies not different in early or late treated patients and LTNP No correlation of total HIV-1 DNA measured in blood and rectal biopsies Early ART (n=14) LTNP (n=8) Late ART (n=29) p=0.375 p=0.337 p=0.259

Cross-sectional study design PCR-based assays for HIV-1 reservoir quantification, not measured replication-competent reservoir (e.g. QVOA) Inadequate power to examine influence of Fiebig stage Qualitative differences in HIV-1 sequence not examined Limitations of the study

Conclusions ↓total and integrated HIV-1 DNA Late treated Reduced reservoir size in blood LTNP ↓usRNA↑ CD4/CD8 ratio LTNP Fast seeding of reservoir and other immunological aspects Late treated Lower transcriptional activity and enhanced immune restoration Late treated Early treated

We thank the study participants for their essential contribution UCL London Sabine Kinloch-de Loes Margaret Jonhson Charles Murray AIDS Reference Laboratory Chris Verhofstede HTRU Linos Vandekerckhove Ward De Spiegelaere Pawel Bonczkowski Maja Kiselinova Wim Trypsteen Sofie Rutsaert Marie-Angélique De Scheerder Clarissa Van Hecke Karen Vervisch UZ Ghent Dirk Vogelaers Steven Callens Erica Sermijn Jolanda Pelgrom Beatrijs Van Der Gucht Filip Van Wanzeele Els Caluwé Danny De Looze Acknowledgements

Thank you!